| |
|
OMT has developed a transgenic rat for the generation of fully human monoclonal antibodies.
Monoclonal antibodies (mAbs) have been the primary focus of drug-development efforts since the early 1990s. Many pharmaceutical companies have entered the biologics market through acquiring antibody technologies or through licensing/fee for service arrangements.
Previously, genetically engineered mice were the only animal-based human antibody platform available for developing new monoclonal antibodies. Pharmaceutical companies interested in licensing the transgenic mouse encountered:
- Limited target availability,
- Significant upfront license costs, and
- Potential milestones and royalty stacking.
The expense and limitations of transgenic mice created an opportunity for OMT — a new monoclonal antibody platform with unrestricted development options.
|
|
|
|
